NANJING VAZYME BIOTECH CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.35 CNY | +1.50% |
|
+8.53% | -36.45% |
| Sales 2024 * | 1.66B 229M | Sales 2025 * | 2.1B 290M | Capitalization | 8.08B 1.11B |
|---|---|---|---|---|---|
| Net income 2024 * | 486M 66.94M | Net income 2025 * | 534M 73.55M | EV / Sales 2024 * | 4.86 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.84 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
16.7
x | Employees | 2,700 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 21.13% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.50% | ||
| 1 week | +8.53% | ||
| Current month | +1.70% | ||
| 1 month | -4.77% | ||
| 3 months | -15.87% | ||
| 6 months | -30.07% | ||
| Current year | -36.45% |
1 week
19.41
20.73
1 month
18.1721.18
Current year
17.5832.40
1 year
17.5841.49
3 years
17.58130.50
5 years
17.58130.50
10 years
17.58130.50
| Managers | Title | Age | Since |
|---|---|---|---|
Lin Cao
CEO | Chief Executive Officer | 45 | 12-02-29 |
Wen Xin Bi
DFI | Director of Finance/CFO | 48 | 16-08-31 |
Guo Yang Zhang
CHM | Chairman | 35 | 12-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kuan Yun Xia
BRD | Director/Board Member | 62 | 20-05-27 |
Jiang Nan Cai
BRD | Director/Board Member | 67 | 20-05-27 |
Lin Cao
CEO | Chief Executive Officer | 45 | 12-02-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +5.84% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 20.35 | +1.50% | 1 461 733 |
| 24-07-16 | 20.05 | 0.00% | 857,289 |
| 24-07-15 | 20.05 | -1.91% | 955,364 |
| 24-07-12 | 20.44 | +1.04% | 1,155,580 |
| 24-07-11 | 20.23 | +4.93% | 1,745,005 |
End-of-day quote Shanghai S.E., July 16, 2024
More quotes
Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in biopharmaceuticals. The Company's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The Company's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
20.35
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.45% | 1.1B | |
| +56.99% | 848B | |
| +31.64% | 627B | |
| +0.03% | 363B | |
| +15.43% | 318B | |
| +12.67% | 299B | |
| +15.51% | 243B | |
| +16.72% | 225B | |
| +16.35% | 179B | |
| +4.13% | 167B |
- Stock Market
- Equities
- 688105 Stock
